EUVIMEDEUVIMED entdecken
Crossref

The safety of modified, all-oral shorter tuberculosis regimens in Armenia

Hakob Atshemyan, Naira Khachatryan, Anush Khachatryan, Narine Mirzoyan

International Journal of Risk & Safety in Medicine · 2024

DOI: 10.3233/jrs-230039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Risk & Safety in Medicine, 2024. Verfasst von Hakob Atshemyan und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Center of Pulmonology, Abovyan, Armenia. Hauptthemen laut MEDLINE: Rifampin, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The implementation of modified, all-oral shorter regimens for treatment of rifampicin-resistant tuberculosis has started in Armenia since August 2020 under the conditions of operational research. OBJECTIVE: This study aims to evaluate the safety and effectiveness of shorter regimens. METHODS: We evaluated cumulative incidence rates of serious adverse events, adverse events of grade 3 and greater and events resulting in treatment modifications or suspension for 52 study participants. RESULTS: A new, different pattern of adverse events emerged compared with the previous evaluations of drug safety of treatment for rifampicin-resistant tuberculosis. Arthralgia (23.1%) and peripheral neuropathy (21.2%) took leading positions among the adverse events resulting in modifications of treatment. Some adverse events of interest (prolonged QT interval, elevated liver enzymes and anemia) remained relevant for the patients receiving new combinations of anti-TB drugs. The other adverse events (impaired hearing, acute kidney injury and hypokalemia) lost their significance for safety surveillance of rifampicin-resistant tuberculosis treatment. One unexpected serious adverse event (lymphoproliferative skin lesion) brought to a “failed treatment” outcome. The other serious adverse event was anemia. CONCLUSION: The shorter regimens proved to be safe and effective for treatment of rifampicin-resistant tuberculosis, but proper follow-up of adverse events is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinAntitubercular AgentsTuberculosis, Multidrug-ResistantHumansMaleFemaleArmeniaAdultMiddle AgedAdministration, OralDrug Administration ScheduleAged

Stichwörter der Autor:innen

Rifampicin-resistant tuberculosisadverse eventsshorter regimens

Substanzen

RifampinAntitubercular Agents

Autor:innen und Institutionen

  • National Center of Pulmonology, Abovyan, Armenia.
  • Yerevan State Medical University after Mkhitar Heratsi, Yerevan, Armenia.

Zitieren

APA

Atshemyan, H., Khachatryan, N., Khachatryan, A., & Mirzoyan, N. (2024). The safety of modified, all-oral shorter tuberculosis regimens in Armenia. International Journal of Risk & Safety in Medicine. https://doi.org/10.3233/jrs-230039

Vancouver

Atshemyan H, Khachatryan N, Khachatryan A, Mirzoyan N. The safety of modified, all-oral shorter tuberculosis regimens in Armenia. International Journal of Risk & Safety in Medicine. 2024. doi:10.3233/jrs-230039

BibTeX
@article{Atshemyan2024,
  author = {Atshemyan, Hakob and Khachatryan, Naira and Khachatryan, Anush and Mirzoyan, Narine},
  title = {The safety of modified, all-oral shorter tuberculosis regimens in Armenia},
  journal = {International Journal of Risk & Safety in Medicine},
  year = {2024},
  doi = {10.3233/jrs-230039}
}
Kostenlos starten →